A
21.49
1.26 (6.20%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Arrowhead Pharmaceuticals, Inc. | Bullish | Bullish |
Stockmoo Score
0.5
|
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 60.00 (Chardan Capital, 179.20%) | Buy |
| 60.00 (HC Wainwright & Co., 179.20%) | Buy | |
| Median | 60.00 (179.20%) | |
| Low | 55.00 (B. Riley Securities, 155.93%) | Buy |
| Average | 58.33 (171.43%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 24.74 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 05 Sep 2024 | 60.00 (179.20%) | Buy | 23.25 |
| 03 Sep 2024 | 60.00 (179.20%) | Buy | 22.91 | |
| B. Riley Securities | 12 Aug 2024 | 55.00 (155.93%) | Buy | 22.94 |
| Chardan Capital | 17 Jul 2024 | 60.00 (179.20%) | Buy | 28.02 |
| 26 Jun 2024 | 60.00 (179.20%) | Buy | 26.26 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |